POST Online Media Lite Edition



 

Experimental Ebola vaccines elicit year-long immune response

Staff Writer |
Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year.

Article continues below






The findings, published in the October 12 issue of the New England Journal of Medicine, are based on a study of 1,500 adults that began during the West Africa Ebola outbreak.

The trial is being conducted by a U.S.-Liberia clinical research collaboration known as the Partnership for Research on Ebola Virus in Liberia (PREVAIL), established in 2014 in response to the request from the Liberian Minister of Health to the U.S. Secretary of Health and Human Services.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and involves scientists and clinicians from Liberia and the United States.

"This clinical trial has yielded valuable information that is essential for the continued development of these two Ebola vaccine candidates and also demonstrates that well-designed, ethically sound clinical research can be conducted during an epidemic," said NIAID Director Anthony S. Fauci, M.D.

"A safe and effective vaccine would be a critically important addition to classical public health measures in controlling inevitable future Ebola outbreaks."

PREVAIL conducts collaborative biomedical research in accordance with best practices, to advance science, strengthen health policy and practice, and improve the health of people in Liberia and around the world.

The partnership launched this first study, PREVAIL 1, in February 2015. Originally designed to enroll 28,000 volunteers, the trial was scaled back to a Phase 2 study when the decline in new Ebola cases made it impossible to conduct a large efficacy study.

"In Liberia, we have demonstrated to the global community that rigorous scientific research can take place in a developing sub-Saharan African country when a mutually beneficial partnership is developed," noted Dr. Bernice T. Dahn, Liberia's Minister of Health.

"The work of PREVAIL, ranging from the Ebola vaccine to the Ebola survivor studies, clearly manifest the prospects of such a sustainable partnership and clinical research platform."

The co-leaders of the trial are Stephen B. Kennedy, M.D., M.P.H., senior research scientist at the University of Liberia-Pacific Institute for Research and Evaluation (UL-PIRE) Africa Center, an infectious disease research center; Fatorma Bolay, Ph.D., director, Public Health and Medical Research at the National Public Health Institute of Liberia; and H. Clifford Lane, M.D., NIAID's clinical director.

The vaccine candidates included cAd3-EBOZ, co-developed by NIAID's Vaccine Research Center and GlaxoSmithKline (GSK); and rVSV-ZEBOV, which was initially engineered by scientists from the Public Health Agency of Canada and is now licensed to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Merck). GSK and Merck provided the test vaccines for the study.

From Feb. 2, 2015, through April 30, 2015, the trial rapidly enrolled men and women ages 18 and older with no reported history of Ebola virus disease at Redemption Hospital in Monrovia.

Three groups of 500 volunteers received one of the vaccine candidates or a placebo (saline injection). Participants provided blood samples before vaccination and again at one week, one month, six months and one year post-vaccination.

Investigators then tested each of these samples for antibodies to the Ebola virus. Responses at one week were modest with both vaccines.

However, by one month, 71 percent of cAd3-EBOZ recipients and 84 percent of rVSV-ZEBOV recipients developed an antibody response compared to 3 percent of placebo recipients.

At one year, antibody responses were largely maintained in both groups: 64 percent of cAd3-EBOZ recipients and 80 percent of rVSV-ZEBOV recipients had an antibody response compared with seven percent of placebo recipients.

Some participants who received the investigational vaccines experienced mild to moderate side effects that resolved, such as headache, muscle pain, feverishness and fatigue.

Overall, investigators did not identify any major safety concerns related to the vaccines. Most of the serious medical issues reported during the trial were due to malaria.

Interestingly, at the beginning of the trial investigators found that 4 percent of participants already had a certain threshold of Ebola antibodies - indicative of past Ebola infection - but no known history of Ebola virus disease.

Investigators also found unexpectedly that the proportion of participants developing malaria by one year was lower for participants who received the investigational vaccines as compared with those receiving placebo, particularly among the rVSV-ZEBOV recipients.

Future studies are needed to determine if this is a chance finding or if it has some significance related to cross-reactive immunity.


What to read next

Researchers find immune system link science said didn't exist
Zika vaccine works in early human trial
Key to long-term malaria vaccine unlocked, say Australian researchers

26 dead after dozens of tornadoes hit several U.S. states

 
At least 26 people have been killed after a series of tornadoes tore through towns and cities in the United States' South and Midwest.
 
 

Latest

6 crew members missing after pirate attack in Gulf of Guinea
Operation Henhouse: Hundreds of arrests and millions in assets seized in month tackling fraud
Brazil: Criminal organization investigated for sending 17 tons of cocaine to Europe dismantled
India successfully conducts reusable launch vehicle autonomous landing mission

NEWS

FAA gives kids opportunity to design airports

Venezuela investigates possible corruption at state metals conglomerate
Two Swiss trains derail in strong winds, several injured
Myanmar extends COVID-19 restrictions until end of April
Raccoon captured in Hawaii
10 people killed in gold mine collapse in Northern Sudan
 

BUSINESS

EPA grants waivers for California’s on-highway heavy-duty vehicle and engine emission standards

Oil and gas rigs cut, Baker Hughes says
Germany invests €39 million in hydrogen chemical research in southeastern Bavaria
Largest ever cash increase in National Living Wage to boost pay for millions in UK
Vancouver’s single-use cup by-law and cup fee repealed effective May 1
Cyprus' shipping significantly reduced
 

Trending Now

Brazil: Criminal organization investigated for sending 17 tons of cocaine to Europe dismantled

Operation Henhouse: Hundreds of arrests and millions in assets seized in month tackling fraud

26 dead after dozens of tornadoes hit several U.S. states

6 crew members missing after pirate attack in Gulf of Guinea


POLITICS

Governor Polis leading Colorado investment mission in Japan

China, Brazil strike deal to ditch dollar in trade
Britain agrees to join trans-Pacific trade pact
Largest investment for housing efforts in Florida
Serbia: EIB Vice-President Pavlova signs second EU grant for Belgrade – Niš railway
Georgia lawmakers agree to pay full tuition for college scholarships
 

Today We Recommend

British Columbia government: Unexplained wealth orders crack down on organized crime


Highlights 

ArcelorMittal’s JV with Nippon Steel secures $5 billion loan for India expansion, to create 60,000+ jobs

Petrofac, Hitachi Energy receive 13 billion euros agreement from TenneT

Lululemon Athletica Q4 revenue increased


COMPANIES

Italy bans ChatGPT, opens probe on privacy concerns, fine may be 20 million euros

JUWI’s Wolf Wind Project in South Africa to generate electricity for grid by Q1 2024
Spain has Europe’s first smart and connected bus to 5G
Michelin backed joint venture to create large scale tire recycling group in Europe
Alstom to deliver advanced rail cybersecurity measures for Hong Kong rail project
ArcelorMittal’s JV with Nippon Steel secures $5 billion loan for India expansion, to create 60,000+ jobs
 

CAREERS

SEACOM announces new group CEO

Appian appoints Douglas Coleman as head of Mexico
DTiQ announces senior leadership appointment
Vanda Pharmaceuticals appoints Tage Honoré to board
Akhona Qengqe to become KFC Africa’s new general manager
Marlabs appoints Usha Jamadagni as chief delivery officer
 

ECONOMY

Texas leads nation with fastest economic expansion

Dutch imports from India increased eightfold since 2002
Highest ever EU trade deficit recorded in 2022
UK economy grows in Q4, avoids recession
U.S. weekly jobless claims rise to 198,000
U.S. consumer confidence unexpectedly improves in March
 

EARNINGS

BlackBerry revenue declined

H.B. Fuller Q1 revenue $809 million
H&M Q1 profit rises
Lululemon Athletica Q4 revenue increased
Cal-Maine Foods Q3 sales $997.5 million
Jefferies Q1 earnings $134 million
 

OP-ED

Micromanaging is the worst enemy of efficiency and teamwork

Niger set to monetize massive gas reserves through Saharan natural gas pipeline
Putting the brakes on EV folly that choked the market
Oil discovery in Kavango Basin may mean huge benefits for Namibians
Cape Town and Dubai battle over Africa's energy future
Is America going to lose its superpower status?
 

AGRIFISH

Plans underway for Australia's biggest vertically-integrated exotic mushroom farm

Earthquakes hit more than 20 percent of Turkiye's food production
Plan proposed to contain invasive forest pest affecting east Tennessee
Spongy moth trapping to continue in Cruso, North Carolina, treatment postponed for 2023
New Zealand: Catch limits cuts for Northland rock lobster
Ireland: Minister Hackett announces commencement of Organic Farming Scheme 2022 balancing payments
 

LEADERSHIP

Acquisitions can nix existing partnerships

Success of working from home depends on company health
Consumers less likely to support brands with unconventional spellings
HR practices have both positive and negative effects on employee mental health
CEO education is no guarantee of stock market success
How remote work affects managers
 

CRIME

Federal Reserve Board fines Wells Fargo $67.8 million

Former CFO of Russian natural gas company Novatek convicted of making false statements to IRS
William Hill almost lost licence, fined record $24 million for gambling failures
UK construction firms fined nearly £60 million for breaking competition law by bid rigging
Former Puerto Rico mayor convicted of accepting bribes
McDonald's fined $53,000 in South Korea for leaking customers data
 

Magazine

TRAVEL

To taste good maple taffy come to Maple Sugar Festival

Watches and Wonders trade fair kicks off in Geneva
Arkansas Times Craft Beer Festival is back and better than ever
laïla, Seychelles opens
Five day street food festival in Mangaluru brings Indian food to city
Qatar International Food Festival is back
 

SEA, LAND, AIR

Alfa Romeo Tonale Edizione Bambini, perfect for family

Dodge Challenger SRT Demon 170, 1,025 HP for your joy
First GMC Sierra EV, power source on wheels
Ford Puma ST Powershift, most powerful 1.0‑litre EcoBoost engine
Toyota launches new Prius PHEV in Japan
Ariel Atom, serious motor sport or ultimate fun
 

DESIGN

Italian coffee makers to feel like a pro

Juliska tableware, collections for every occasion
Wool coats, a timeless fashion investment
Venetto bedding, creating a beautiful bedroom space
Bed headboards, sleep like a king
Great rugs for generations responsibly made
 

GADGETS

Audeze CRBN electrostatic headphone, from medicine to audio

Focal Vestia N°3, floorstanding loudspeaker for accomplished performance
New Cherry microphones for professional sound quality
Mobile Fidelity UltraDeck turntable, extreme pursuit of highest level of reproduction
Nokia G22, good smartphone you can fix yourself
NAD C 3050 LE amplifier, a classic reinvented
 

HEALTH

North Carolinians urged to "Fight the Bite" with insect repellant to avoid tick-and mosquito-borne disease

Killer plant fungus infects man in India in world first case
EMA recommends approval of Bimervax as COVID-19 booster vaccine
China plans random, spot checks at hospitals to track COVID
FDA approves first over the counter naloxone nasal spray
British Columbia takes actions to prevent shortage of diabetes drug
 

MEANTIME

City of Toronto launches 2023 Clean Toronto Together spring cleanup campaign

Rare total solar eclipse on horizon for April 2024
World's population to decline
Supermassive black hole 30 billion times the mass of our Sun discovered
China’s Chang’e-5 lander finds potential water reservoir on moon
Park Board: Help keep Vancouver’s Canada goose population in check